Electron impact mass spectrometry of some 2,3-dihydro-1-benzofuran-3-acetic acids
摘要:
AbstractThe mass spectrometric behaviour of four 2,3‐dihydro‐1‐benzofuran‐3‐acetic acids has been studied in detail with the aid of exact mass measurements, linked scans, collisionally activated decomposition, mass analysed ion kinetic energy spectra and labelling experiments. Unusual fragmentation pathways are emphasized for which mechanisms are proposed.
Electron impact mass spectrometry of some 2,3-dihydro-1-benzofuran-3-acetic acids
摘要:
AbstractThe mass spectrometric behaviour of four 2,3‐dihydro‐1‐benzofuran‐3‐acetic acids has been studied in detail with the aid of exact mass measurements, linked scans, collisionally activated decomposition, mass analysed ion kinetic energy spectra and labelling experiments. Unusual fragmentation pathways are emphasized for which mechanisms are proposed.
The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof. The compound or a salt thereof or a prodrug thereof has a GPR40 receptor function modulating action and is useful as an insulin secretagogue or an agent for the prophylaxis or treatment of diabetes and the like.
The present invention provides a compound represented by the formula (I):
wherein each symbol is as defined in the description, or a salt thereof. The compound or a salt thereof or a prodrug thereof has a GPR40 receptor function modulating action and is useful as an insulin secretagogue or an agent for the prophylaxis or treatment of diabetes and the like.
Fused cyclic compounds as GPR40 receptor modulators
申请人:Takeda Pharmaceutical Company Limited
公开号:EP2431367A2
公开(公告)日:2012-03-21
The present invention provides a compound represented by the formula (I):
wherein each symbol is as defined in the description, or a salt thereof, and pharmaceutical compositions comprising said compound, useful as insulin secretagogues or agents for the treatment of the diabetes (GPR40 receptor modulators).